Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

Koichiro Yoneyama, Mizuki Fukazawa-Shinotsuka, Tomohisa Saito

Blood (2022) 140 (Supplement 1): 2740–2741.

https://doi.org/10.1182/blood-2022-155934

Published: 2022

Journal Articles

Quantitative Estimation of the In Vivo Equivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data

Koichiro Yoneyama, Tetsuhiro Soeda, Kazuki Yamaguchi, Takuya Miwa, Takaaki Ishida, Tomohisa Saito

Blood (2022) 140 (Supplement 1): 11295–11296.

https://doi.org/10.1182/blood-2022-155918

Published: 2022

Journal Articles

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors

Koichiro Yoneyama, Kazuo Tokuda, Tetsuhiro Soeda, Tomohisa Saito, Midori Shima

Blood (2021) 138 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2021-144549

Published: 2021

Journal Articles

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Midori Shima, MD, Sayaka Nagami, BSc, Koichiro Yoneyama, MSc, Akira Nomura, MSc, Yoshiyuki Ogawa, MD PhD, Kagehiro Amano, MD PhD, Keiji Nogami, MDPhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136488

Published: 2020

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects

Naoki Uchida, Takehiko Sambe, Koichiro Yoneyama, Naoki Fukazawa, Takehiko Kawanishi, Shinichi Kobayashi, Midori Shima

Blood (2016) 127 (13): 1633–1641.

https://doi.org/10.1182/blood-2015-06-650226

Published: 2016

Includes: Supplemental data

Journal Articles

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Midori Shima, MD PhD, Hideji Hanabusa, MD, Masashi Taki, MDPhD, Tadashi Matsushita, MD PhD, Tetsuji Sato, MD, Katsuyuki Fukutake, MD PhD, Naoki Fukazawa, Shingo Maisawa, Koichiro Yoneyama, Keiji Nogami, MD PhD

Blood (2014) 124 (21): 691.

https://doi.org/10.1182/blood.V124.21.691.691

Published: 2014

NARROW

A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

Quantitative Estimation of the In Vivo Equivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

Quantitative Estimation of the In Vivo Equivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only